Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The provision of Drugs that have recently lost exclusivity
Framework contract: £5,577,339 total value shared among 3 suppliers. Estimated equal shares shown below.
| Supplier | Identifier | Est. Share | Lots Won | Cross-References |
|---|---|---|---|---|
| Janssen Ltd | 08072203 | ~£1,859,113 | 1 lot Lot 1 | LOBBYIST Ovid Consulting Ltd (2 quarters) M&F Health (1 quarter) |
| Mercury Pharmaceuticals Ltd | 02619880 | ~£1,859,113 | 1 lot Lot 1 | - |
| Teva UK Ltd | 00302461 | ~£1,859,113 | 1 lot Lot 1 | - |
Taken from this notice, not from Companies House. Check the original notice — details change and are not updated here.
This procurement was divided into 1 lots, each awarded separately. 9 bids were received in total.
| Lot | Value | Bids Received | Awarded To | Status |
|---|---|---|---|---|
| Lot 1 Jan 2026 – Dec 2027 | £45,077,163 £5,577,339 initial term | 9 | Mercury Pharmaceuticals Ltd Teva UK Ltd Janssen Ltd | active |
Weightings from the notice.
Government spending data: These suppliers have received £84,876,679 in 181 payments (over £25k) from Department of Health and Social Care, NHS England, Guy's and St Thomas' NHS FT, Maidstone and Tunbridge Wells NHS Trust, BEIS (2010-07-22 to 2026-03-12).